EPCAM and cancer: Taken together, our data demonstrate that both EpCAM-ReTARGTPRvIL2 and EpCAM-ReTARGTPRIFNαR149A selectively bind to EpCAMpos cancer cells, whereupon their respective cytokine muteins attain enhanced biological activity.